A subsequent study revealed that compared to those treated with TNF-α inhibitors, patients on baricitinib for rheumatoid arthritis had an elevated risk of encountering adverse cardiovascular events and venous thromboembolism (Register, 2021). The gene discussed is TNF; the disease is rheumatoid arthritis.